by Keitaro Yokoyama, Akio Nakashima, Mitsuyoshi Urashima, Hiroaki Suga, Takeshi Mimura, Yasuo Kimura, Yasushi Kanazawa, Tamotsu Yokota, Masaya Sakamoto, Sho Ishizawa, Rimei Nishimura, Hideaki Kurata, Yudo Tanno, Katsuyoshi Tojo, Shigeru Kageyama, Ichiro Ohkido, Kazunori Utsunomiya, Tatsuo Hosoya
We aimed to examine associations among serum 25-hydroxyvitamin D (25OHD) levels, 1,25-dihyroxyvitamin D (1,25OHD) levels, vitamin D receptor (VDR) polymorphisms, and renal function based on estimated glomerular filtration rate (eGFR) in patients with type 2 diabetes. Methods
In a cross-sectional study of 410 patients, chronic kidney disease (CKD) stage assessed by eGFR was compared with 25OHD, 1,25OHD, and VDR FokI (rs10735810) polymorphisms by an ordered logistic regression model adjusted for the following confounders: disease duration, calendar month, use of angiotensin converting enzyme inhibitors/angiotensin receptor blockers or statins, and serum calcium, phosphate, and intact parathyroid hormone levels. Results
1,25OHD levels, rather than 25OHD levels, showed seasonal oscillations; peak levels were seen from May to October and the lowest levels were seen from December to February. These findings were evident in patients with CKD stage 3~5 but not stage 1~2. eGFR was in direct proportion to both 25OHD and 1,25OHD levels (P<0.0001), but it had stronger linearity with 1,25OHD (r?=?0.73) than 25OHD (r?=?0.22) levels. Using multivariate analysis, 1,25OHD levels (P<0.001), but not 25OHD levels, were negatively associated with CKD stage. Although FokI polymorphisms by themselves showed no significant associations with CKD stage, a significant interaction between 1,25OHD and FokITT was observed (P?=?0.008). The positive association between 1,25OHD and eGFR was steeper in FokICT and CC polymorphisms (r?=?0.74) than FokITT polymorphisms (r?=?0.65). Conclusions
These results suggest that higher 1,25OHD levels may be associated with better CKD stages in patients with type 2 diabetes and that this association was modified by FokI polymorphisms.